Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anusha Pusuluri

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
Journal of Controlled Release : Official Journal of the Controlled Release Society|April 21, 2019
Immunological consequences of chemotherapy: Single drugs, combination therapies and nanoparticle-based treatmentsAnusha Pusuluri, Debra Wu, Samir Mitragotri
Bioengineering & Translational Medicine|January 30, 2018
Schedule dependent synergy of gemcitabine and doxorubicin: Improvement of in vitro efficacy and lack of in vitro-in vivo correlationDouglas R Vogus, Anusha Pusuluri, Renwei Chen, et al.
Bioengineering & Translational Medicine|June 29, 2019
Role of synergy and immunostimulation in design of chemotherapy combinations: An analysis of doxorubicin and camptothecinAnusha Pusuluri, Vinu Krishnan, Debra Wu, et al.
Pharmaceutics|January 20, 2021
Optimized 5-Fluorouridine Prodrug for Co-Loading with Doxorubicin in Clinically Relevant LiposomesDebra Wu, Douglas Vogus, Vinu Krishnan, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|April 14, 2020
Design principles of drug combinations for chemotherapyDebra Wu, Anusha Pusuluri, Douglas Vogus, et al.
Angewandte Chemie (International Ed. in English)|December 12, 2018
Treating Tumors at Low Drug Doses Using an Aptamer-Peptide Synergistic Drug ConjugateAnusha Pusuluri, Vinu Krishnan, Valerie Lensch, et al.
Nature Chemistry|May 25, 2017
Engineering live cell surfaces with functional polymers via cytocompatible controlled radical polymerizationJia Niu, David J Lunn, Anusha Pusuluri, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|April 2, 2016
DAFODIL: A novel liposome-encapsulated synergistic combination of doxorubicin and 5FU for low dose chemotherapyKathryn M Camacho, Stefano Menegatti, Douglas R Vogus, et al.
ACS Chemical Biology|September 19, 2019
Click-Particle Display for Base-Modified Aptamer DiscoveryChelsea K L Gordon, Diana Wu, Anusha Pusuluri, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|August 22, 2017
A hyaluronic acid conjugate engineered to synergistically and sequentially deliver gemcitabine and doxorubicin to treat triple negative breast cancerDouglas R Vogus, Michael A Evans, Anusha Pusuluri, et al.
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Journal of Controlled Release : Official Journal of the Controlled Release Society|April 21, 2019
Immunological consequences of chemotherapy: Single drugs, combination therapies and nanoparticle-based treatmentsAnusha Pusuluri, Debra Wu, Samir Mitragotri
Bioengineering & Translational Medicine|January 30, 2018
Schedule dependent synergy of gemcitabine and doxorubicin: Improvement of in vitro efficacy and lack of in vitro-in vivo correlationDouglas R Vogus, Anusha Pusuluri, Renwei Chen, et al.
Bioengineering & Translational Medicine|June 29, 2019
Role of synergy and immunostimulation in design of chemotherapy combinations: An analysis of doxorubicin and camptothecinAnusha Pusuluri, Vinu Krishnan, Debra Wu, et al.
Pharmaceutics|January 20, 2021
Optimized 5-Fluorouridine Prodrug for Co-Loading with Doxorubicin in Clinically Relevant LiposomesDebra Wu, Douglas Vogus, Vinu Krishnan, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|April 14, 2020
Design principles of drug combinations for chemotherapyDebra Wu, Anusha Pusuluri, Douglas Vogus, et al.
Angewandte Chemie (International Ed. in English)|December 12, 2018
Treating Tumors at Low Drug Doses Using an Aptamer-Peptide Synergistic Drug ConjugateAnusha Pusuluri, Vinu Krishnan, Valerie Lensch, et al.
Nature Chemistry|May 25, 2017
Engineering live cell surfaces with functional polymers via cytocompatible controlled radical polymerizationJia Niu, David J Lunn, Anusha Pusuluri, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|April 2, 2016
DAFODIL: A novel liposome-encapsulated synergistic combination of doxorubicin and 5FU for low dose chemotherapyKathryn M Camacho, Stefano Menegatti, Douglas R Vogus, et al.
ACS Chemical Biology|September 19, 2019
Click-Particle Display for Base-Modified Aptamer DiscoveryChelsea K L Gordon, Diana Wu, Anusha Pusuluri, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|August 22, 2017
A hyaluronic acid conjugate engineered to synergistically and sequentially deliver gemcitabine and doxorubicin to treat triple negative breast cancerDouglas R Vogus, Michael A Evans, Anusha Pusuluri, et al.
Pageof 2